More recently, the DREAMseq trial (EA 6134) confirmed that initial ICI treatment with ipilimumab/nivolumab produced superior progression-free and overall survival, as well as improved response duration, compared to initial therapy with dabrafenib/trametinib in patients with BRAF mutant melanoma [23]. Here, BRAF is linked to melanoma.